Phaseline

Companies › Angitia

Angitia: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Other; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AGA2115
Unclear mechanism targeting COL1A1 and/or COL1A2 genetic variations in osteogenesis imperf
–Phase 2Osteogenesis Imperfecta (OI)Nov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07062588AGA2115Phase 2Osteogenesis Imperfecta (OI)OtherNov 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Zynerba Pharmaceuticals Nocion Therapeutics Angitia Biopharmaceuticals Guangzhou Next Life Sciences Aelis Farma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.